Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CONCORD HEALTHCARE GROUP CO., LTD.
美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

VOLUNTARY ANNOUNCEMENT
APPROVAL FOR INCLUSION OF THE COMPANY INTO THE LIST OF DESIGNATED MEDICAL INSTITUTIONS UNDER THE MEASURE OF USING HONG KONG REGISTERED DRUGS AND MEDICAL DEVICES USED IN HONG KONG PUBLIC HOSPITALS IN GUANGDONG-HONG KONG-MACAO GREATER BAY AREA

This announcement is made by the board of directors (the "**Board**") of Concord Healthcare Group Co., Ltd. (the "**Company**") on a voluntary basis.

The Board is pleased to announce that on December 8, 2025, Guangzhou Concord Cancer Center (廣州泰和腫瘤醫院), a subsidiary of the Company, was approved by Health Commission of Guangdong Province and Guangdong Provincial Medical Products Administration to be included into the list of designated medical institutions under the Measure of Using Hong Kong Registered Drugs And Medical Devices Used in Hong Kong Public Hospitals In Guangdong-Hong Kong-Macao Greater Bay Area (the "Measure") (港澳藥械通).

The Measure is a core implementation measure under the Work Plan for Supervision, Innovation and Development of Drugs and Medical Device in the Guangdong-Hong Kong-Macao Greater Bay Area. Designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area included in the list may import and use products under the special medical policies for Guangdong-Hong Kong-Macao Greater Bay Area upon approval. The Measure allows designated medical institutions to use clinically urgent drugs and advanced medical devices already marketed in Hong Kong and Macao after obtaining approval.

This qualification certification positions the Company as one of the specialized oncology medical institutions authorized to utilize innovative drugs and medical devices marketed in Hong Kong and Macau. The Company can now take the lead in introducing and utilizing urgently needed oncology drugs and medical devices that have been approved in Hong Kong and Macau but not yet in Chinese Mainland, including innovative original drugs. This initiative will further expand the Company's business scope, establish a differentiated competitive advantage in the market, provide urgently needed pharmaceutical products to more cancer patients, and simultaneously strengthen the Company's competitive edge in the field of oncology healthcare.

This initiative will also drive deeper integration between the Company and medical resources in Hong Kong and Macau, enhancing clinical treatment standards and research capabilities. By introducing cutting-edge international pharmaceuticals and medical devices, it will optimize cancer treatment protocols, and accelerate alignment with global healthcare standards, help establish a high-level cancer diagnosis and treatment system, and continuously improve patient service experiences and treatment outcomes.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, December 8, 2025

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. Song Qingbao and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.